Award

ADVANCE PURCHASE AGREEMENT FOR SARS-CoV-2/COVID-19 VACCINE

BUSINESS ENERGY AND INDUSTRIAL STRATEGY

This public procurement record has 1 release in its history.

Award

12 Feb 2021 at 17:45

Summary of the contracting process

The public procurement process involves an advance purchase agreement for the SARS-CoV-2/COVID-19 vaccine, primarily managed by the Business Energy and Industrial Strategy, located at 1 Victoria Street, London, UK. This procurement falls under the goods category, specifically dealing with vaccines, and was initiated under extreme urgency without prior publication as per the Public Contracts Regulations 2015. The contract was signed on 15 January 2021, and the award has been made to Janssen Pharmaceutica NV, with the procurement conducted using a limited method due to the urgent requirement arising from the pandemic.

This tender represents a significant opportunity for businesses involved in pharmaceutical manufacturing, particularly those developing vaccine candidates. Companies offering related healthcare products or services may also find viable opportunities to engage in supply chains or related contracts. With the heightened demand for vaccines during the ongoing pandemic, this procurement opens doors for manufacturers and suppliers capable of delivering critical products quickly, offering them a chance to expand their market reach and contribute to public health efforts.

Find more tenders on our Open Data Platform.
How relevant is this notice?

D3 Tenders Premium

Win More Public Sector Contracts

AI-powered tender discovery, pipeline management, and market intelligence — everything you need to grow your public sector business.

Notice Title

ADVANCE PURCHASE AGREEMENT FOR SARS-CoV-2/COVID-19 VACCINE

Notice Description

Procurement of Janssen's vaccine candidate Ad26.COV2-S.

Lot Information

Lot 1

This contract has been procured using the negotiated procedure without prior publication under regulation 32 of the Public Contracts Regulations 2015 on the basis that the award of the contract to Janssen is strictly necessary for unforeseeable reasons of extreme urgency; i.e. the urgent requirement to secure priority access to a viable vaccine to end the Covid-19 pandemic (Regulation 32(2)(c)). Additional information: Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vaccine vendors and (iii) impact fair competition between vaccine vendors.

Procurement Information

The award of the contract to Janssen is strictly necessary for unforeseeable reasons of extreme urgency; i.e. the urgent requirement to find a viable vaccine to end the Covid 19 pandemic (Regulation 32(2)(c)).

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-029301
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/002970-2021
Current Stage
Award
All Stages
Award

Procurement Classification

Notice Type
Award Notice
Procurement Type
Standard
Procurement Category
Goods
Procurement Method
Limited
Procurement Method Details
Award procedure without prior publication of a call for competition
Tender Suitability
Not specified
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products


CPV Codes

33651600 - Vaccines

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
£1

Notice Dates

Publication Date
12 Feb 20215 years ago
Submission Deadline
Not specified
Future Notice Date
Not specified
Award Date
15 Jan 20215 years ago
Contract Period
Not specified - Not specified
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Cancelled
Awards Status
Active
Contracts Status
Active

Contracting Authority (Buyer)

Main Buyer
BUSINESS ENERGY AND INDUSTRIAL STRATEGY
Contact Name
Not specified
Contact Email
vtfcontracts@beis.gov.uk
Contact Phone
Not specified

Buyer Location

Locality
LONDON
Postcode
SW1H 0ET
Post Town
South West London
Country
England

Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI3 Inner London - West
Small Region (ITL 3)
TLI35 Westminster and City of London
Delivery Location
TLE Yorkshire and The Humber

Local Authority
Westminster
Electoral Ward
St James's
Westminster Constituency
Cities of London and Westminster

Supplier Information

Number of Suppliers
1
Supplier Name

JANSSEN PHARMACEUTICA

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

Download

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-029301-2021-02-12T17:45:33Z",
    "date": "2021-02-12T17:45:33Z",
    "ocid": "ocds-h6vhtk-029301",
    "initiationType": "tender",
    "tender": {
        "id": "4846/01/2021",
        "legalBasis": {
            "id": "32014L0024",
            "scheme": "CELEX"
        },
        "title": "ADVANCE PURCHASE AGREEMENT FOR SARS-CoV-2/COVID-19 VACCINE",
        "status": "complete",
        "classification": {
            "scheme": "CPV",
            "id": "33651600",
            "description": "Vaccines"
        },
        "mainProcurementCategory": "goods",
        "description": "Procurement of Janssen's vaccine candidate Ad26.COV2-S.",
        "lots": [
            {
                "id": "1",
                "description": "This contract has been procured using the negotiated procedure without prior publication under regulation 32 of the Public Contracts Regulations 2015 on the basis that the award of the contract to Janssen is strictly necessary for unforeseeable reasons of extreme urgency; i.e. the urgent requirement to secure priority access to a viable vaccine to end the Covid-19 pandemic (Regulation 32(2)(c)). Additional information: Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vaccine vendors and (iii) impact fair competition between vaccine vendors.",
                "awardCriteria": {
                    "criteria": [
                        {
                            "type": "price"
                        }
                    ]
                },
                "hasOptions": false,
                "status": "cancelled"
            }
        ],
        "items": [
            {
                "id": "1",
                "deliveryAddresses": [
                    {
                        "region": "BE"
                    }
                ],
                "relatedLot": "1"
            }
        ],
        "procurementMethod": "limited",
        "procurementMethodDetails": "Award procedure without prior publication of a call for competition",
        "coveredBy": [
            "GPA"
        ],
        "procurementMethodRationaleClassifications": [
            {
                "scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
                "id": "D_EXTREME_URGENCY",
                "description": "Extreme urgency brought about by events unforeseeable for the contracting authority/entity and in accordance with the strict conditions stated in the directive"
            }
        ],
        "procurementMethodRationale": "The award of the contract to Janssen is strictly necessary for unforeseeable reasons of extreme urgency; i.e. the urgent requirement to find a viable vaccine to end the Covid 19 pandemic (Regulation 32(2)(c))."
    },
    "awards": [
        {
            "id": "002970-2021-4846/01/2021-1",
            "relatedLots": [
                "1"
            ],
            "title": "ADVANCE PURCHASE AGREEMENT FOR SARS-CoV-2/COVID-19 VACCINE",
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-FTS-5607",
                    "name": "JANSSEN PHARMACEUTICA NV"
                }
            ]
        }
    ],
    "parties": [
        {
            "id": "GB-FTS-5606",
            "name": "Business Energy and Industrial Strategy",
            "identifier": {
                "legalName": "Business Energy and Industrial Strategy"
            },
            "address": {
                "streetAddress": "1 Victoria Street",
                "locality": "London",
                "region": "UK",
                "postalCode": "SW1H0ET",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "email": "VTFContracts@beis.gov.uk"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.gov.uk/government/organisations/department-for-business-energy-and-industrial-strategy",
                "classifications": [
                    {
                        "scheme": "TED_CA_TYPE",
                        "id": "MINISTRY",
                        "description": "Ministry or any other national or federal authority, including their regional or local subdivisions"
                    },
                    {
                        "scheme": "COFOG",
                        "id": "01",
                        "description": "General public services"
                    }
                ]
            }
        },
        {
            "id": "GB-FTS-5607",
            "name": "JANSSEN PHARMACEUTICA NV",
            "identifier": {
                "legalName": "JANSSEN PHARMACEUTICA NV"
            },
            "address": {
                "streetAddress": "30 Turnhoutseweg",
                "locality": "Beerse",
                "region": "BE",
                "postalCode": "B-2340",
                "countryName": "Belgium"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-5608",
            "name": "Department of Business, Energy and Industrial Strategy",
            "identifier": {
                "legalName": "Department of Business, Energy and Industrial Strategy"
            },
            "address": {
                "streetAddress": "1 Victoria Street",
                "locality": "London",
                "postalCode": "SW1H 0ET",
                "countryName": "United Kingdom"
            },
            "roles": [
                "reviewBody"
            ]
        }
    ],
    "buyer": {
        "id": "GB-FTS-5606",
        "name": "Business Energy and Industrial Strategy"
    },
    "contracts": [
        {
            "id": "002970-2021-4846/01/2021-1",
            "awardID": "002970-2021-4846/01/2021-1",
            "title": "ADVANCE PURCHASE AGREEMENT FOR SARS-CoV-2/COVID-19 VACCINE",
            "status": "active",
            "value": {
                "amount": 1,
                "currency": "GBP"
            },
            "dateSigned": "2021-01-15T00:00:00Z"
        }
    ],
    "bids": {
        "statistics": [
            {
                "id": "1",
                "measure": "bids",
                "relatedLot": "1",
                "value": 1
            }
        ]
    },
    "language": "en"
}